Latest Breaking News On - Mihaelh polymeropoulos - Page 9 : comparemela.com

Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

/PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported positive results in a Phase III clinical study of Fanapt® (iloperidone.

United statesMihaelh polymeropoulosKevin moranVanda pharmaceuticals incHarvard medical schoolNational comorbidity survey replicationPrnewswire vanda pharmaceuticals incExchange commissionHead of corporate affairsNational comorbidity surveySupplemental new drug applicationYoung mania rating scaleClinician global impressionNew drug applicationMedical schoolComorbidity survey

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

District of columbiaUnited statesSan franciscoMihaelh polymeropoulosUniversity of californiaVanda pharmaceuticals incDrug administrationPrnewswire vanda pharmaceuticals incTropical disease priority review voucher programExchange commissionTreasurervanda pharmaceuticals incOrphan drug designationDrug designationPriority review voucherInvestigational new drugTropical diseases

Vanda Pharmaceuticals (VNDA) Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

Vanda Pharmaceuticals (VNDA) Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mihaelh polymeropoulosVanda pharmaceuticals incTropical disease priority review voucher programDrug administrationOrphan drug designationDrug designationPriority review voucherInvestigational new drugTropical diseases

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

/PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug.

District of columbiaUnited statesSan franciscoMihaelh polymeropoulosKevin moranUniversity of californiaVanda pharmaceuticals incDrug administrationPrnewswire vanda pharmaceuticals incTropical disease priority review voucher programExchange commissionHead of corporate affairsOrphan drug designationDrug designationPriority review voucherInvestigational new drug

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

/PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug.

District of columbiaUnited statesSan franciscoMihaelh polymeropoulosKevin moranUniversity of californiaVanda pharmaceuticals incDrug administrationPrnewswire vanda pharmaceuticals incTropical disease priority review voucher programExchange commissionHead of corporate affairsOrphan drug designationDrug designationPriority review voucherInvestigational new drug